NRX-204647 is a potent activator of retinoic acid nuclear (RAR) with higher specificity than that to RAR and RAR. NRX-204647 can inhibit bone formation. NRX-204647 significantly reduces bone volume/tissue volume (BV/TV). NRX-204647 can be studied in anti-cancer research [1] [2].
References:
[1]. Uchibe, K., et al., (2017). Genetic and pharmacological inhibition of retinoic acid receptor γ function promotes endochondral bone formation. Journal of orthopaedic research: official publication of the Orthopaedic Research Society, 35(5), 1096-1105.
[2]. Garcia, S. A., et al., (2020). Understanding the Action of RARγ Agonists on Human Osteochondroma Explants. International journal of molecular sciences, 21(8), 2686.
References:
[1]. Uchibe, K., et al., (2017). Genetic and pharmacological inhibition of retinoic acid receptor γ function promotes endochondral bone formation. Journal of orthopaedic research: official publication of the Orthopaedic Research Society, 35(5), 1096-1105.
[2]. Garcia, S. A., et al., (2020). Understanding the Action of RARγ Agonists on Human Osteochondroma Explants. International journal of molecular sciences, 21(8), 2686.